Next generation renal denervation

June 2015 - Cardiovascular Revascularization Medicine

This paper co-authored by MAF-1 portfolio company Ablative Solutions’ Tim Fischell, Vartan Ghazarossian, et al, describes the preclinical results, in a porcine model, and the early first-in-man results, using the Peregrine™ chemical renal denervation catheter to perform renal sympathetic denervation using micro-doses of alcohol. The paper concludes that perivascular RDN using micro-doses of alcohol is a promising alternative to energy-based systems to achieve dose-dependent, predictable, safe and essentially painless renal denervation. Further clinical evaluation is warranted more